CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma
Giulia Giorgetti(Dana-Farber Cancer Institute), Michele Cea(Ospedale Policlinico San Martino), Anaïs Schavgoulidze(Inserm), Andrea Benzi(University of Genoa), Daniela Fenoglio(Ospedale Policlinico San Martino), Alessio Nencioni(Ospedale Policlinico San Martino), Fabio Guolo(Ospedale Policlinico San Martino), Roberto M. Lemoli(University of Genoa), Santina Bruzzone(University of Genoa), Aimable Nahimana(University of Lausanne), Pamela Becherini(Ospedale Policlinico San Martino), Nikhil C. Munshi(Dana-Farber Cancer Institute), Mariateresa Fulciniti(Dana-Farber Cancer Institute), Antonia Cagnetta(Ospedale Policlinico San Martino), Chiara Uras(University of Genoa), Silvia Ravera(Ospedale Policlinico San Martino), Debora Soncini(University of Genoa), Giulia Rivoli(Ospedale Policlinico San Martino), Elena Maroto-Martín(Harvard University), Francesco Ladisa(Dana-Farber Cancer Institute), Francesco Lai(Ospedale Policlinico San Martino), Isabella Traverso(University of Genoa), Jessica Fong Ng(Harvard University)
Cited by 3
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906